

PERSONAL INFORMATION **Johanna Lahteenvuo**

WORK EXPERIENCE

June 2001-September 2009 **researcher**
University of Kuopio (Finland)
Basic research (gene therapy, cardiovascular diseases)

September 2009-December 2011 **Research fellow in medicine**
Harvard Medical School, Center for Life Sciences (United States)
Basic research (cardiovascular diseases)

January 2012-July 2016 **University Reasercher**
University of Eastern Finland (Finland)

August 2016-March 2018 **Assistant professor (tenure track)**
Univeristy of Eastern Finland (Finland)

May 2018- Present **Senior Medical Officer**
Finnish Medicined Agency Fimea (Finland)
Marketing authorizations, scientific advice

EDUCATION AND TRAINING

September 2000-September 2009 **MD, PhD**
University of Kuopio (Finland)

ADDITIONAL INFORMATION

Expertise Gene therapy, cell therapies, molecular medicine, cardiovascular diseases, haematology

Publications Publications Johanna Lahteenvuo (nee Markkanen)
Lahteenvuo J, Hatinen OP, Kuivanen A, Huusko J, Paananen J, Lahteenvuo M, Nurro J, Hedman M, Hartikainen J, Laham-Karam N, Makinen P, Rasanen M, Alitalo K, Rosenzweig A, Yla-Herttuala S
Susceptibility to Cardiac Arrhythmias and Sympathetic Nerve Growth in VEGF-B Overexpressing Myocardium.
Mol Ther. 2020 Mar 19. pii: S1525-0016(20)30145-3. doi: 10.1016/j.ymthe.2020.03.011.
Hatinen OA, Lahteenvuo JE, Korpela HJ, Pajula JJ, Yla-Herttuala S.
Isolation of fresh endothelial cells from porcine heart for cardiovascular studies: a new fast protocol suitable for genomic, transcriptomic and cell biology studies.
BMC Mol Cell Biol. 2019 Aug 13;20(1):32. doi: 10.1186/s12860-019-0215-2
Laakkonen JP, Lahteenvuo J, Jauhiainen S, Heikura T, Yla-Herttuala S.
Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta.
Vascul Pharmacol. 2019 Jan;112:91-101. doi: 10.1016/j.vph.2018.10.005. Epub 2018 Oct 17.
Review
Lahteenvuo J, Yla-Herttuala S.
Advances and Challenges in Cardiovascular Gene Therapy
Hum Gene Ther. 2017 Aug 15. doi: 10.1089/hum.2017.129. [Epub ahead of print]
Nurro J Nurro J, Halonen PJ, Kuivanen A, Tarkia M, Saraste A, Honkonen K, Lahteenvuo J, Rissanen TT, Knuuti J, Yla-Herttuala S.

AdVEGF-B186 and AdVEGF-DNC induce angiogenesis and increase perfusion in porcine myocardium.
Heart. 2016 Nov 1;102(21):1716-1720

Lahteenvuo J, Rosenzweig A.
Effects of Aging on Angiogenesis
Circ Res. Epub 2012 April 27

Lahteenvuo M, Honkonen K, Tervala T, Tammela T, Suominen E, Lahteenvuo J, Kholova I, Alitalo K, Yla-Herttuala S, Saaristo A.
Growth factor therapy and autologous lymph node transfer in lymphedema.
Circulation. 2011 Feb 15;123(6):613-20. Epub 2011 Jan 31

Roy H, Bhardwaj S, Babu M, Lahteenvuo JE, Yla-Herttuala S.
VEGF-DeltaNdeltaC mediated angiogenesis in skeletal muscles of diabetic WHHL rabbits.
Eur J Clin Invest. 2010 May;40(5):422-32.

Viita H, Kinnunen K, Eriksson E, Lahteenvuo J, Babu M, Kalesnykas G, Heikura T, Laidinen S, Takalo T, Yla-Herttuala S.
Intravitreal adenoviral 15-lipoxygenase-1 gene transfer prevents vascular endothelial growth factor A-induced neovascularization in rabbit eyes.
Hum Gene Ther. 2009 Dec;20(12):1679-86

Toivanen PI, Nieminen T, Viitanen L, Alitalo A, Roschier M, Jauhiainen S, Markkanen JE, Laitinen OH, Airene TT, Salminen TA, Johnson MS, Airene KJ, Yla-Herttuala S.
Novel vascular endothelial growth factor D (VEGF-D) variants with increased biological activity.
J Biol Chem. 2009 Apr 14.

Lahteenvuo, J.E., Lahteenvuo, M.T., Kivela, A., Heikura, T., Rissanen, T.T., Vahakangas, E., Korpisalo, P., Enholm, B., Carmeliet, P., Alitalo, K., Eriksson, U. & Yla-Herttuala, S.
VEGF-B induces myocardium specific angiogenesis and arteriogenesis via VEGFR-1 and Nrp-1 dependent mechanisms.
Circulation. 2009 Feb 17;119(6):845-56. Epub 2009 Feb 2.

Korpisalo P, Rissanen TT, Bengtsson T, Liimatainen T, Laidinen S, Karvinen H, Markkanen JE, Grohn OH, Yla-Herttuala S.
Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs.
Cardiovasc Res. 2008 Aug 5.

Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M, Heikura T, Turpeinen S, Laidinen S, Takalo T, Yla-Herttuala S.
5-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression.
Circ Res. 2008 Feb 1;102(2):177-84. Epub 2007 Nov 8.

Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, Yla-Herttuala S, Alitalo K.
Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein.
Circ Res. 2007 May 25;100(10):1460-7. Epub 2007 May 3.

Tammela T, He Y, Lyytikka J, Jeltsch M, Markkanen J, Pajusola K, Yla-Herttuala S, Alitalo K.
Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Circ Res. 2007 May 25;100(10):1468-75. Epub 2007 May 3.

Rissanen TT, Korpisalo P, Markkanen JE, Liimatainen T, Orden MR, Kholova I, de Goede A, Heikura T, Grohn OH, Yla-Herttuala S.
Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis.
Circulation. 2005 Dec 20;112(25):3937-46. Epub 2005 Dec 12.

Markkanen JE, Rissanen TT, Kivela A, Yla-Herttuala S.
Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart--gene therapy.
Cardiovasc Res. 2005 Feb 15;65(3):656-64. Review.

Yla-Herttuala S, Markkanen JE, Rissanen TT.

Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials.

Trends Cardiovasc Med. 2004 Nov;14(8):295-300. Review

Gruchala M, Bhardwaj S, Pajusola K, Roy H, Rissanen TT, Kokina I, Kholova I, Markkanen JE, Rutanen J, Heikura T, Alitalo K, Bueler H, Yla-Herttuala S.

Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors.

J Gene Med. 2004 May;6(5):545-54.

Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A, Hedman A, Hedman M, Heikura T, Orden MR, Stacker SA, Achen MG, Hartikainen J, Yla-Herttuala S.

Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.

Circulation. 2004 Mar 2;109(8):1029-35. Epub 2004 Feb 16.

Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholova I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Yla-Herttuala S.

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.

Circ Res. 2003 May 30;92(10):1098-106. Epub 2003 Apr 24.

Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I, Jauhiainen S, Cashion L, Gruchala M, Narvanen O, Taipale P, Kauppinen RA, Rubanyi GM, Yla-Herttuala S.

Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model.

FASEB J. 2003 Jan;17(1):100-2. Epub 2002 Nov 15.

Rissanen TT, Vajanto I, Hiltunen MO, Rutanen J, Kettunen MI, Niemi M, Leppanen P, Turunen MP, Markkanen JE, Arve K, Alhava E, Kauppinen RA, Yla-Herttuala S.

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration.

Am J Pathol. 2002 Apr;160(4):1393-403.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)